- Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study
[作者:Paschka, P; Marcucci, G; Ruppert, AS; Whitman, SP; Mrozek, K; Maharry, K; Langer, C; Baldus, CD; Zhao, WQ; Powell, BL; Baer, MR; Carroll, AJ; Caligiuri, MA; Kolitz, JE; Larson, RA; Bloomfield, CD,期刊:Journal of clinical oncology, 页码:4595-4602 , 文章类型: Article,,卷期:2008年26-28]
- PurposeTo analyze the prognostic impact of Wilms' tumor 1 (WT1) gene mutations in cytogenetically normal acute myeloid leukemia (CN-AML).Patients and MethodsWe studied 196 adults younger than 60 years with newly diagnose...
- Psychosocial factors and survival of young women with breast cancer: A population-based prospective cohort study
[作者:Phillips, KA; Osborne, RH; Giles, GG; Dite, GS; Apicella, C; Hopper, JL; Milne, RL,期刊:Journal of clinical oncology, 页码:4666-4671 , 文章类型: Article,,卷期:2008年26-28]
- PurposeMost women with early-stage breast cancer believe that psychosocial factors are an important influence over whether their cancer will recur. Studies of the issue have produced conflicting results.Patients and Meth...
- Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: A Cancer and Leukemia Group B study
[作者:Neubauer, A; Maharry, K; Mrozek, K; Thiede, C; Marcucci, G; Paschka, P; Mayer, RJ; Larson, RA; Liu, ET; Bloomfield, CD,期刊:Journal of clinical oncology, 页码:4603-4609 , 文章类型: Article,,卷期:2008年26-28]
- PurposeRAS mutations occur in 12% to 27% of patients with acute myeloid leukemia (AML) and enhance sensitivity to cytarabine in vitro. We examined whether RAS mutations impact response to cytarabine in vivo.Patients and ...
- Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
[作者:Schneider, BP; Wang, M; Radovich, M; Sledge, GW; Badve, S; Thor, A; Flockhart, DA; Hancock, B; Davidson, N; Gralow, J; Dickler, M; Perez, EA; Cobleigh, M; Shenkier, T; Edgerton, S; Miller, KD,期刊:Journal of clinical oncology, 页码:4672-4678 , 文章类型: Article,,卷期:2008年26-28]
- PurposeNo biomarkers have been identified to predict outcome with the use of an antiangiogenesis agent for cancer. Vascular endothelial growth factor ( VEGF) genetic variability has been associated with altered risk of b...
- Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer
[作者:Tanvetyanon, T; Eikman, EA; Sommers, E; Robinson, L; Boulware, D; Bepler, G,期刊:Journal of clinical oncology, 页码:4610-4616 , 文章类型: Article,,卷期:2008年26-28]
- PurposeTumor response is considered a surrogate marker of survival. We investigated whether tumor response based on computed tomography (CT) scan or whole-body [F-18] fluorodeoxyglucose positron emission tomography (PET)...
- Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer
[作者:Pusztai, L; Broglio, K; Andre, F; Symmans, WF; Hess, KR; Hortobagyi, GN,期刊:Journal of clinical oncology, 页码:4679-4683 , 文章类型: Article,,卷期:2008年26-28]
- PurposeThe majority of estrogen receptor ( ER)-positive cancers are sensitive to endocrine therapy and may not derive much further benefit from chemotherapy, but a subset are potentially chemotherapy sensitive. Molecular...
- Primary mediastinal germ cell tumor evolving into an extramedullary acute megakaryoblastic leukemia causing cord compression
[作者:Brahmanday, GR; Gheorghe, G; Jaiyesimi, IA; Orazi, A; Zekman, R; Parikh, R; Wills, SM; Einhorn, LH,期刊:Journal of clinical oncology, 页码:4686-4688 , 文章类型: Article,,卷期:2008年26-28]
-
|